| Primary |
| Acute Lymphocytic Leukaemia |
21.8% |
| Febrile Neutropenia |
10.9% |
| Atypical Mycobacterial Infection |
7.3% |
| Septic Shock |
7.3% |
| Tuberculosis |
7.3% |
| Staphylococcal Infection |
5.5% |
| Staphylococcal Sepsis |
5.5% |
| Cholangitis |
3.6% |
| Febrile Bone Marrow Aplasia |
3.6% |
| Gastrooesophageal Reflux Disease |
3.6% |
| Hypertension |
3.6% |
| Pain |
3.6% |
| Pseudomonas Infection |
3.6% |
| Anticoagulant Therapy |
1.8% |
| Anxiety |
1.8% |
| Atrial Fibrillation |
1.8% |
| Bronchitis |
1.8% |
| Candidiasis |
1.8% |
| Cardiac Failure |
1.8% |
| Erysipelas |
1.8% |
|
| Renal Failure Acute |
15.8% |
| Thrombocytopenia |
10.5% |
| Completed Suicide |
5.3% |
| Cytolytic Hepatitis |
5.3% |
| Jaundice |
5.3% |
| Lymphopenia |
5.3% |
| Pancreatitis |
5.3% |
| Pancytopenia |
5.3% |
| Pleural Effusion |
5.3% |
| Purpura |
5.3% |
| Rash |
5.3% |
| Rash Maculo-papular |
5.3% |
| Skin Exfoliation |
5.3% |
| Tinnitus |
5.3% |
| Toxic Skin Eruption |
5.3% |
| Urticaria |
5.3% |
|
| Secondary |
| Acute Myeloid Leukaemia |
11.9% |
| Bronchopulmonary Aspergillosis |
11.0% |
| Drug Use For Unknown Indication |
10.8% |
| Pyrexia |
7.1% |
| Tuberculosis |
6.2% |
| Lung Disorder |
5.4% |
| Sepsis |
5.4% |
| Pneumonia |
5.2% |
| Sedation |
4.2% |
| Epilepsy |
3.7% |
| Mycobacterium Abscessus Infection |
3.7% |
| Abscess |
3.3% |
| Hiv Infection |
3.3% |
| Status Epilepticus |
3.1% |
| Unevaluable Event |
2.9% |
| Acute Lymphocytic Leukaemia |
2.7% |
| Aplasia |
2.5% |
| Atypical Mycobacterial Infection |
2.5% |
| Bronchitis |
2.5% |
| Colorectal Cancer Metastatic |
2.5% |
|
| Toxic Skin Eruption |
17.2% |
| Septic Shock |
10.8% |
| Vertigo |
9.7% |
| Skin Exfoliation |
7.5% |
| Thrombocytopenia |
7.5% |
| Ventricular Fibrillation |
6.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
5.4% |
| Status Epilepticus |
5.4% |
| Dermatitis Allergic |
3.2% |
| Rash |
3.2% |
| Renal Tubular Necrosis |
3.2% |
| Stevens-johnson Syndrome |
3.2% |
| Acquired Haemophilia |
2.2% |
| Cerebellar Syndrome |
2.2% |
| Fistula |
2.2% |
| Lymphopenia |
2.2% |
| Pyrexia |
2.2% |
| Rash Vesicular |
2.2% |
| Tonic Clonic Movements |
2.2% |
| Transaminases Increased |
2.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
31.9% |
| Product Used For Unknown Indication |
18.5% |
| Acute Lymphocytic Leukaemia |
12.8% |
| Pyrexia |
3.8% |
| Tuberculosis |
3.6% |
| Hyperthermia |
3.1% |
| Hiv Infection |
2.8% |
| Prophylaxis |
2.5% |
| Caecitis |
2.0% |
| Osteitis |
2.0% |
| Unevaluable Event |
2.0% |
| Acute Myeloid Leukaemia |
1.8% |
| Burkitt's Lymphoma |
1.8% |
| Lung Disorder |
1.8% |
| Bone Marrow Transplant |
1.7% |
| Bone Pain |
1.7% |
| Induction Of Anaesthesia |
1.7% |
| Pneumonia Streptococcal |
1.7% |
| Infection |
1.6% |
| Infection Prophylaxis |
1.3% |
|
| Thrombocytopenia |
16.5% |
| Pyrexia |
9.6% |
| Rash Maculo-papular |
7.0% |
| Graft Versus Host Disease |
5.2% |
| Rash Morbilliform |
5.2% |
| Renal Failure Acute |
5.2% |
| Thrombotic Microangiopathy |
5.2% |
| Vomiting |
5.2% |
| Weight Decreased |
5.2% |
| Febrile Bone Marrow Aplasia |
4.3% |
| Tumour Lysis Syndrome |
4.3% |
| Pancreatitis Acute |
3.5% |
| Pancytopenia |
3.5% |
| Septic Shock |
3.5% |
| Transaminases Increased |
3.5% |
| Agranulocytosis |
2.6% |
| Cholestasis |
2.6% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.6% |
| Eosinophilic Pneumonia |
2.6% |
| Jaundice |
2.6% |
|
